Strategies for Cardio-Oncology Care During the COVID-19 Pandemic.
Sonu AbrahamShamitha Alisa ManoharRushin PatelAnu Mariam SajiSourbha S DaniSarju GanatraPublished in: Current treatment options in cardiovascular medicine (2022)
Patient-centric policies are helpful for cardio-oncology surveillance like remote monitoring, increased use of biomarker-based surveillance, imaging modalities like CT scan, and point-of-care ultrasound to minimize the exposure for high-risk patients. Abundant prior experience in cancer therapy scaffolded the repurposed use of corticosteroids, IL-6 inhibitors, and Janus kinase inhibitors in the treatment of COVID-19 infection. COVID-19 vaccine timing and dose frequency present a challenge due to overlapping toxicities and immune cell depletion in patients receiving cancer therapies. The SARS-CoV-2 pandemic laid bare social and ethnic disparities in healthcare but also steered in innovation to combat problems of patient outreach, particularly with virtual care. In the recovery phase, the backlog in cardio-oncology care, interplay of cancer therapy-related side effects, and long COVID-19 syndrome are crucial issues to address.
Keyphrases
- sars cov
- healthcare
- palliative care
- cancer therapy
- coronavirus disease
- public health
- case report
- respiratory syndrome coronavirus
- affordable care act
- drug delivery
- end stage renal disease
- computed tomography
- quality improvement
- mental health
- newly diagnosed
- chronic kidney disease
- ejection fraction
- pain management
- magnetic resonance imaging
- high resolution
- molecular dynamics
- papillary thyroid
- prognostic factors
- squamous cell carcinoma
- dual energy
- patient reported outcomes
- magnetic resonance
- health information
- photodynamic therapy
- fluorescence imaging
- mass spectrometry
- squamous cell